近日，国内稀缺的专注于"血液流向管理"的平台型介入创新企业江苏臻亿医疗科技有限公司（以下简称"臻亿医疗"）宣布完成C轮数亿元融资。本轮融资 由东方富海、国元股权、厦门产投/创投、厦金创新、博正资本、思明科创等联合投资，老股东生命树资本继续加持。此次C轮融资是臻亿医疗在短短数年 内完成的多轮重要资本动作之一，资本持续追投，体现了市场对公司平台化布局、技术创新能力及商业化前景的高度认可，也标志着国产心血管介入企业 在高端器械领域的突破进入新阶段。 臻亿医疗成立于2019年，着重专注致死致残率极高且国内市场仍是空白的心血管疾病领域，以"臻于至善，亿万之重"为使命，迅速崛起成为中国高端医疗 器械行业中一股不可忽视的新兴力量。企业业务全面覆盖心脏瓣膜、外周、冠脉等多个介入治疗领域，是率先在全球范围内实现血液流向管理一站式创新 解决方案的平台化企业。成立至今，公司保持高速成长节奏，2023年完成B+轮融资后，公司研发、注册与临床推进全面加速。此次C轮融资的成功，为其 进入规模化商业阶段与国际化拓展阶段提供了坚实支撑。 中伦律师事务所为臻亿医疗本次融资提供了全流程法律服务，包括起草、修改交易文件，商务谈判，协助完成交割等法 ...

近日， 江苏臻亿医疗科技有限公司（以下简称"臻亿医疗"）宣布完成 C轮数亿元融资 。 本轮融资由东方富海、国元直投、厦门产投/创投、博正资本、厦金创新、 思明科创联合投资，老股东生命树资本继续加持。 这是臻亿医疗近几年完成的又一轮关键融资，资本持续追投，体现了市场对公司平台化布局、技术创新能力及商业化前景的高度认可，也标志着国产心血管介入企 业在高端器械领域的突破进入新阶段。 # 行业背景：结 构性 心脏病进入 介入治疗加速期 随着我国人口老龄化进程加快，瓣膜性心脏病、心衰及外周血管疾病的发病率持续上升。传统开胸手术创伤大、恢复慢，对高龄或高危患者不友好，临床迫切需要 更安全、微创、可重复的介入治疗方案。 近年来，以经导管二尖瓣、三尖瓣修复与置换为代表的结构性心脏病介入治疗成为全球心血管领域的重要创新方向。然而，长期以来，高端瓣膜介入器械被跨国巨 头垄断，国产替代率极低，国内市场仍存在巨大的空白与临床需求缺口。 在此背景下，臻亿医疗率先聚焦"血液流向管理"赛道，通过技术创新和系统化布局，为中国患者提供更可及、更精准的国产化治疗选择。 # 公司定位：打 造" 血 液流 向管理" 平台 经导管二尖瓣置换系统（Tr ...

Core Insights - Jiangsu Zhenyi Medical Technology Co., Ltd. has completed a C-round financing of several hundred million yuan, focusing on "blood flow management" in the high-end medical device sector [2][3] - The financing was led by multiple institutions including Dongfang Fuhai, Guoyuan Equity, and others, indicating strong investor interest in innovative medical solutions [2] Company Overview - Zhenyi Medical is recognized as an innovative high-end medical device company, focusing on high mortality and disability rate diseases that remain unaddressed in the domestic market [2] - The company has a comprehensive business coverage across four major disease areas: heart valve, heart failure, peripheral, and coronary artery diseases, making it the first domestic company to fully engage in these critical sectors [2] Innovation and Product Development - The company has applied for over 160 patents, with 80% being invention patents and more than 40 PCT international patents, showcasing its commitment to innovation [2] - Currently, over 15 projects are under research, with four key products—mitral valve repair, tricuspid valve repair, mitral valve replacement, and shockwave balloon—rapidly advancing through clinical registration [2] - These products have received widespread recognition from patients, clinical doctors, and industry peers, positioning Zhenyi Medical as a leader in the domestic market [2] Strategic Expansion Plans - The chairman of Zhenyi Medical emphasized the need for a nationwide base network to support the launch of multiple innovative products and accelerate product development [3] - The company plans to establish a high-end production cluster in the Yangtze River Delta, with a focus on R&D in Shanghai, and aims to create research and production centers in key regions [3] - Zhenyi Medical intends to leverage domestic clinical resources to build specialized education and operation centers, exploring new paths for international medical cooperation and advancing its global strategy [3]